Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Cross-bridge Cycle01:26

Cross-bridge Cycle

118.1K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
118.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

677
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
677
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Chemical Synapses01:26

Chemical Synapses

9.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Participant Experiences with EMPOWER: Benefits, Barriers, and Best Practices for an Online Peer Mentorship and Leadership Program for Women in Academic Medicine.

Women's health reports (New Rochelle, N.Y.)·2026
Same author

Diabetes and the Metabolic Syndrome as Drivers of Neurodegeneration: Convergent Mechanisms Linking Peripheral Neuropathy and Dementia.

Annals of neurology·2026
Same author

Voluntary wheel running decreases intraepidermal nerve fibers in healthy mice.

Pain reports·2026
Same author

Peripheral Neutrophil Activation and Extracellular Trap Formation in Amyotrophic Lateral Sclerosis.

Annals of clinical and translational neurology·2026
Same author

Metabolic and Microvascular Risk Factors Associated With Brain Health in Type 1 Diabetes.

Annals of clinical and translational neurology·2026
Same author

Diabetic Peripheral Neuropathy May Be an Independent Risk Marker for Dementia and Cerebrovascular Disease.

Diabetes, obesity & metabolism·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Aug 28, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.7K

Esclerosis lateral amiotrófica

Eva L Feldman1, Stephen A Goutman1, Susanne Petri2

  • 1Department of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

Lancet (London, England)
|September 18, 2022
PubMed
Resumen

El tratamiento de la esclerosis lateral amiotrófica (ELA) está mejorando con nuevos criterios de diagnóstico y la comprensión de su naturaleza compleja. Los avances en fisiopatología, biomarcadores y terapias ofrecen la esperanza de mejores resultados para los pacientes.

Más Videos Relacionados

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.2K

Videos de Experimentos Relacionados

Last Updated: Aug 28, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.7K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.2K

Área de la Ciencia:

  • La neurociencia
  • Neurología

Sus antecedentes:

  • La esclerosis lateral amiotrófica (ELA) es una enfermedad neurodegenerativa fatal del sistema nervioso central (SNC) con un tratamiento actual subóptimo.
  • La heterogeneidad fenotípica y la disfunción global del SNC caracterizan la ELA, lo que requiere mejores enfoques de diagnóstico y pronóstico.

Objetivo del estudio:

  • Para esbozar las ideas recientes sobre la fisiopatología, el diagnóstico y el pronóstico de la ELA.
  • Discutir el estado actual y las perspectivas futuras del manejo de la ELA para los neurólogos.

Principales métodos:

  • Revisión de la investigación actual sobre la heterogeneidad, la genética y la fisiopatología de la ELA.
  • Análisis de nuevos criterios de diagnóstico, biomarcadores, factores de riesgo y modelos predictivos.
  • Examen de la línea de ensayos clínicos para terapias basadas en mecanismos.

Principales resultados:

  • El reconocimiento de la ELA como un síndrome complejo está impactando la práctica clínica.
  • Los avances en la comprensión de la ELA están aclarando su espectro y facilitando el diagnóstico.
  • Los nuevos conocimientos están cambiando el panorama del pronóstico, aunque el beneficio para el paciente está pendiente.

Conclusiones:

  • A pesar de los desafíos, la investigación emergente ofrece efectos tangibles en la clínica para la ELA.
  • Las perspectivas futuras incluyen una mejor atención y resultados para los pacientes con esclerosis lateral amiotrófica.
  • La investigación continua sobre la fisiopatología y las terapias de la ELA es crucial para el avance clínico.